EGI
PLRX icon

EAM Global Investors’s Pliant Therapeutics PLRX Stock Holding History

EAM Global Investors’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-76,076
Closed -$1.59M – 222
2022
Q3 		$1.59M Buy
+76,076
New +$1.46M 0.42% 127

Other funds holding PLRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

EAM Global Investors's PLRX Position: Q4 2022 in Review

EAM Global Investors sold out of Pliant Therapeutics (PLRX) in Q4 2022, closing a stake of 76,076 shares — an estimated $1.59M sold.

EAM Global Investors first reported a position in PLRX in Q3 2022 and held it in 1 quarter. The position peaked at $1.59M in Q3 2022. 125 funds tracked by Wall St. Rank hold PLRX as of Q4 2022.

  • EAM Global Investors reported no remaining Pliant Therapeutics position as of Q4 2022 after selling out during the quarter.
  • EAM Global Investors sold 76,076 Pliant Therapeutics shares in Q4 2022, an estimated $1.59M.
  • EAM Global Investors first reported a position in Pliant Therapeutics in Q3 2022 and held it in 1 quarter.
  • EAM Global Investors's Pliant Therapeutics position peaked at $1.59M in Q3 2022.
  • 125 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q4 2022.

Based on EAM Global Investors's 13F filing for Q4 2022, filed 14 Feb 2023.